Schering AG及TAP制药公司正在就口服有效的选择性黄体酮受体调节剂asoprisnil(J-867)进行Ⅲ期临床实验,以考察该药长期治疗子宫纤维素瘤的情况。研究发现,一些病人用药后出现子宫内膜病变,但大多在停药后可逆转。作为正在进行的扩展试验的一部分,研究人员继续对这些病人进行跟 Schering AG and TAP Pharmaceuticals are conducting a phase III clinical trial of an oral potent and selective progesterone receptor modulator asoprisnil (J-867) to investigate the long-term treatment of uterine fibroids. The study found that some patients after treatment of endometrial lesions, but most can be reversed after withdrawal. As part of an ongoing pilot extension, researchers continued to follow these patients